New Delhi:India recorded 10,197 new COVID-19 cases in the last 24 hours, 15 per cent higher than the previous day when it had recorded 8,865 new coronavirus infections, the lowest in 287 days. At least 12,134 people recovered from the infection in a day while the country recorded 301 deaths in the last 24 hours.
The active coronavirus caseload stands at 1,28,555 – lowest in 527 days.
The daily positivity rate is 0.82 per cent, less than 2 per cent for the last 44 days while the weekly positivity rate is 0.96 per cent — less than 2 per cent for last 54 days.The active COVID-19 cases in India have declined to 1,28,555.
Of the 10,197 new cases, 12,134 recoveries & 301 deaths in last 24 hrs. Kerala reported 5516 cases, 6705 recoveries and 39 deaths.
In view of the rising COVID-19 cases in Jammu, the district administration has imposed a Corona curfew under section 144 CRPC from 10:00 PM to 06:00 AM instead of 11:00 PM to 05:00 AM in the territorial jurisdiction of the district .COVID-19 cases and the positivity rate has increased beyond 0.2 per cent in Jammu.
Mizoram state has also reported 459 new cases and 1 death. Active cases 5390
On Tuesday US pharmaceutical giant Pfizer announced a deal to make its prospective anti viral Covid-19 pill available more cheaply in the world’s least wealthy countries.
Pfizer will sub-licence production of its promising Paxlovid pill to generic drug manufacturers for supply in 95 low- and middle-income nations covering around 53 percent of the world’s population.
Under the deal struck with the global Medicines Patent Pool (MPP), Pfizer — which also produces one of the most widely-used Covid vaccines with German lab BioNTech — will not receive royalties from the generic manufacturers, making the treatment cheaper.
The agreement is subject to the oral antiviral medication passing ongoing trials and regulatory approval.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
